IOVA
Iovance Biotherapeutics, Inc.
October 29, 2026 · pre-market
- Rarity
- 4.00
- Peak move
- −31.80%
- Float cap
- $5.2B
Still running — rarity and peak move can only rise from here.
Iovance Biotherapeutics is a commercial-stage biopharmaceutical company developing and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumor cancers. It sells Amtagvi (lifileucel), a one-time individualized T cell therapy for previously treated advanced melanoma, and Proleukin (aldesleukin), an IL-2 product used in the Amtagvi regimen and other oncology, manufacturing, and research applications. Products are provided through authorized treatment centers, distributors, and third-party clients.
Where do you see this going?
no votes yetVote to see the split.
What we found
no events · 0 from SEC or newswire · 0 timed with the moveNothing found.We searched SEC filings, the newswires and the open web across the three days around this move and found no public information that explains it.